Contrast-enhanced CT radiomics for predicting lymph node metastasis in pancreatic ductal adenocarcinoma: a pilot study

Ke Li1†, Qiandong Yao2†, Jingjing Xiao3, Meng Li3, Jiali Yang4, Wenjing Hou1, Mingshan Du1, Kang Chen1, Yuan Qu1, Lian Li1, Jing Li1, Xianqi Wang1, Haoran Luo1, Jia Yang5, Zhuoli Zhang5 and Wei Chen1*

Abstract

Background: We developed a computational model integrating clinical data and imaging features extracted from contrast-enhanced computed tomography (CECT) images, to predict lymph node (LN) metastasis in patients with pancreatic ductal adenocarcinoma (PDAC).

Methods: This retrospective study included 159 patients with PDAC (118 in the primary cohort and 41 in the validation cohort) who underwent preoperative contrast-enhanced computed tomography examination between 2012 and 2015. All patients underwent surgery and lymph node status was determined. A total of 2041 radiomics features were extracted from venous phase images in the primary cohort, and optimal features were extracted to construct a radiomics signature. A combined prediction model was built by incorporating the radiomics signature and clinical characteristics selected by using multivariable logistic regression. Clinical prediction models were generated and used to evaluate both cohorts.

Results: Fifteen features were selected for constructing the radiomics signature based on the primary cohort. The combined prediction model for identifying preoperative lymph node metastasis reached a better discrimination power than the clinical prediction model, with an area under the curve of 0.944 vs. 0.666 in the primary cohort, and 0.912 vs. 0.713 in the validation cohort.

Conclusions: This pilot study demonstrated that a noninvasive radiomics signature extracted from contrast-enhanced computed tomography imaging can be conveniently used for preoperative prediction of lymph node metastasis in patients with PDAC.

Keywords: Pancreatic ductal adenocarcinoma, Radiomics, CT, Lymph node metastasis

Background

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease and the fourth leading cause of cancer-related death worldwide, although it is predicted to become the second leading cause by 2030 [1, 2]. PDAC has a poor prognosis, and the 5-year survival rate for all stages is approximately 6%; whereas after surgical resection, the 5-year survival rate can reach 25% [3–6]. Lymph node (LN) metastasis is an independent prognostic factor in PDAC, and preoperative chemotherapy can improve the prognosis of node-positive patients [7–10]. Therefore, accurate preoperative identification of LN involvement in patients with PDAC is crucial for predicting prognosis and for designing better treatment strategies. However, postoperative pathological specimens are generally needed for detecting LN metastasis. In recent years, novel serum markers such as MMP7, MUC1, MUC2, and NLR have been proposed for detecting LN metastases preoperatively.
in PDAC patients [11–13]. However, their clinical application is limited because of technical and accuracy issues.

Computed tomography (CT), which is commonly used in preoperative work-up, is important for the preoperative diagnosis of LN metastasis in PDAC patients, in clinical practice. CT relies on the identification of enlarged LNs to diagnose metastasis. However, the significance of enlarged LNs in PDAC is not well defined. Enlarged LNs can be due to local inflammation or biliary obstruction, and metastatic LNs may not be enlarged [14–17]. Radiomics is a rapidly developing discipline that converts medical images into high-dimensional, mineable data via high-throughput extraction of quantitative features to reflect cellular and biological changes in tissues [18–21]. Two previous studies showed that CT radiomics can predict the malignant potential of intraductal papillary mucinous neoplasms, with important implications for clinical decision-making [22, 23]. However, standardized studies, including large sample sizes are needed to confirm the reliability of this method.

The purpose of this study was to investigate the value of radiomics features extracted from contrast-enhanced CT (CECT), combined with clinical information, for the preoperative prediction of LN metastasis in patients with PDAC.

**Materials and methods**

**Patients**

This retrospective study included a primary cohort of patients who underwent surgical resection of PDAC, between January 2012 and December 2014 at Southwest Hospital (Chongqing, China). A patient recruitment flowchart and inclusion and exclusion criteria are described (Fig. 1). The primary cohort comprised 118 patients, including 82 men and 36 women with a mean age of 57.75 ± 10.28 years. Between January 2015 and December 2015, 41 consecutive patients were recruited using the same criteria as that used for the primary cohort; they constituted the independent validation cohort, comprising 23 men and 18 women with a mean age of 58.32 ± 9.85 years. Ethical approval was obtained from the Ethics Committee of Southwest Hospital, Third Military Medical University (approval No.KY201802) and informed consent requirements were waived.

**Clinical and histopathological analyses**

Surgical specimens were evaluated for pathological grading and LN metastasis according to the World Health Organization 2010 and AJCC 8th edition criteria [24, 25]. Clinical data included age, gender, carcinoembryonic antigen (CEA) levels, cancer antigen-19–9 (CA19–9) levels,
and total bilirubin (TBIL) levels. The threshold values were 5 μg/L for CEA, 35 U/mL for CA 19–9, and 22 μmol/L for TBIL, based on normal ranges as determined in our hospital.

CT protocols and radiographic evaluations
Patients with PDAC were scanned on a dual-source MDCT scanner (FLASH, Siemens Healthineers). The scanning protocol was as follows: 120 kVp, 300 mA, 0.6–0.8 pitch and 128 × 0.6 mm. CT scans of patients included both arterial and venous phases according to institutional protocols. Patients received an injection of 100–120 mL of iohexol (Omnipaque, GE Healthcare) via the cubital vein before scanning. Arterial phase imaging was performed using bolus triggering, approximately 30–40 s after injection, and venous phase imaging was performed approximately 60–70 s after injection. Images were reconstructed into 2 mm sizes for radiographic evaluation and reconstructed into 1 mm sizes for segmentation and radiomics analysis.

CECT images were retrospectively analyzed by two radiologists (one with 8 years of abdominal imaging experience and one with 10 years of abdominal imaging experience) who were blinded to the clinical and pathological data. Assessments included the following: (1) lesion location (head, body or tail); (2) LN status based on abdominal imaging evaluation criteria (location, size, shape, and LN enhancement) [26, 27]. If the evaluation results were different, the final data were obtained after consultation between the two observers. The original evaluation results were retained for consistency analysis.

Image segmentation and radiomics feature extraction
The venous phase image was selected for image segmentation because it was more accurate for displaying the lesion boundary. The region of interest (ROI) of the lesions was delineated manually by two radiologists using in-house developed computer-aided segmentation tools (QJImageEditor, Quanjing Medical Co. Ltd.) and segmented in 3D. The ROI included cystic and necrotic lesions, whereas blood vessels and lymph nodes were not included (Fig. 2). Subsequent feature extraction was performed to select the segmentation area common to both radiologists. The original segmentation results were retained for consistency analysis.

The pyradiomics package (http://www.radiomics.io/pyradiomics.html) was used for feature extraction.

Statistical analysis
Statistical analysis was performed using R software (version 3.5.3, http://www.r-project.org). Significance was two-sided, and $p < 0.05$ was considered statistically significant.
Consistency test
The Kappa consistency test examined the diagnostic results of two radiologists regarding lesion location and LN status. To evaluate the consistency of segmentation results, intersection-over-union (IoU) was used as an evaluation metric and calculated with the following formula:

\[
\text{IoU}(a_A, a_B) = \frac{a_A \cap a_B}{a_A \cup a_B}
\]

where \(a_A\) and \(a_B\) represent the segmented areas of the same patient’s data obtained by each radiologist.

Feature selection and radiomics signature construction
The Z-score was standardized for the extracted features. The least absolute shrinkage and selection operator (LASSO) method, which is suitable for the reduction of high dimensional data [28], was used to select optimal predictive features from the primary cohort. Its performance was verified using a 10-fold cross-validation approach. Features with nonzero coefficients in the LASSO regression model were selected. Then, multivariable logistic regression analysis was used to build a prediction model base on the feature selected. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to evaluate the predictive ability of the model, and its verification on the validation cohort. The radiomics signature of each patient was the linear combination of selected features weighted by their coefficients, denoted as:

\[
\sum_{i=1}^{n} \beta_0 + \beta_i \times X_i
\]

Where \(\beta_0\) is the intercept, \(X_i\) is the \(i\)th selected feature and \(\beta_i\) is the coefficient of the \(i\)th selected feature.

Establishment of clinical and combined prediction models
Univariate analysis assessed the relationship between the clinical characteristics of the patients and LN metastasis in the primary cohort, including age, gender, pathological grading, CEA levels, CA19-9 levels, TBIL levels, and lesion location. The univariate analysis results are shown in Table 1.

| Characteristic               | Primary Cohort | Validation Cohort |
|-----------------------------|----------------|-------------------|
|                             | LN Metastasis (+) | LN Metastasis (+) | p       | LN Metastasis (+) | LN Metastasis (+) | p       |
| Age, mean ± SD, years       | 58.75 ± 10.07    | 56.95 ± 10.44     | 0.348   | 59.12 ± 9.69      | 57.75 ± 10.13     | 0.667   |
| Gender, No. (%)             |                |                   | 0.647   |                  | 0.767   |
| Male                        | 35 (67.3)       | 47 (71.2)         |        | 10 (58.8)        | 13 (54.2)        |        |
| Female                      | 17 (33.7)       | 19 (28.8)         |        | 7 (41.2)         | 11 (45.8)        |        |
| CEA level, No (%)           | 0.185           |                   | 0.273   |                  |                  |
| Normal                      | 41 (78.8)       | 58 (87.9)         |        | 10 (58.8)        | 18 (75.0)        |        |
| Abnormal                    | 11 (21.2)       | 8 (12.1)          |        | 7 (41.2)         | 6 (25.0)         |        |
| CA19–9 level, No (%)        | 0.116           |                   | 0.529   |                  |                  |
| Normal                      | 13 (25.0)       | 9 (13.6)          |        | 5 (29.4)         | 5 (20.8)         |        |
| Abnormal                    | 39 (75.0)       | 57 (86.4)         |        | 12 (70.6)        | 19 (79.2)        |        |
| TBIL level, No (%)          | 0.281           |                   | 0.729   |                  |                  |
| Normal                      | 19 (36.5)       | 18 (27.3)         |        | 4 (23.5)         | 8 (33.3)         |        |
| Abnormal                    | 33 (63.5)       | 48 (72.7)         |        | 13 (76.5)        | 16 (66.7)        |        |
| Lesion location, No (%)     | 0.595           |                   | 0.262   |                  |                  |
| Head                        | 43 (82.7)       | 52 (78.8)         |        | 15 (88.2)        | 17 (70.8)        |        |
| Body or tail                | 9 (17.3)        | 14 (21.2)         |        | 2 (11.8)         | 7 (29.2)         |        |
| CT-reported LN status, No (%)| 0.020*          |                   | 0.019*  |                  |                  |
| LN- positive                | 34 (65.4)       | 29 (43.9)         |        | 12 (70.6)        | 8 (33.3)         |        |
| LN- negative                | 18 (34.6)       | 37 (56.1)         |        | 5 (29.4)         | 16 (66.7)        |        |
| Pathological grade          | 0.008*          |                   | 0.022*  |                  |                  |
| Well                        | 8 (15.4)        | 22 (33.3)         |        | 3 (17.6)         | 11 (45.8)        |        |
| Moderately                  | 17 (32.7)       | 24 (36.4)         |        | 6 (35.3)         | 9 (37.5)         |        |
| Poorly                      | 27 (51.9)       | 20 (30.3)         |        | 8 (47.1)         | 4 (16.7)         |        |

Abbreviations: CEA carcinoembryonic antigen, CA19–9 cancer antigen-19-9, TBIL total bilirubin, CT computed tomography, LN lymph node, SD standard deviation
* highlights the p values that are smaller than 0.05
CT-reported lesion location and CT-reported LN status. Continuous variables were assessed using independent t-tests or Mann-Whitney U tests, and categorical variables were evaluated using chi-square tests, Kruskal-Wallis tests, or Fisher’s exact tests. Statistically significant variables were included in the multivariate logistic regression analysis, and clinical predictive models were established. The combined prediction model was built by integrating the radiomics signature and the selected clinical characteristics.

Model validation and evaluation
The predictive ability of the clinical and combined prediction models was assessed in the primary cohort using ROC curve analysis. Integrated discrimination improvement (IDI) was performed to determine whether differences in predictive ability between the two models were statistically significant. The best performing model was then presented as a nomogram. The logistic regression formula used in the primary cohort was applied to the validation cohort for verification.

A calibration curve was plotted to assess consistency between the estimated probability and the actual rate of LN metastasis, together with a Hosmer-Lemeshow test in the two cohorts [29]. A decision curve analysis was performed to evaluate the clinical usefulness of the nomogram, by quantifying the net benefits at different threshold probabilities [30].

Results
Consistency test results
Both radiologists showed good consistency in determining lesion locations and LN status (kappa coefficient = 0.914 and 0.897, respectively). The IoU scores of each patient are shown (Fig. 2). The average IoU score was 0.89, indicating that consistency was high.

Fig. 3 Radiomics feature selection using the least absolute shrinkage and selection operator (LASSO) binary logistic regression model. a Optimal parameter (lambda) selection in the LASSO model used 10-fold cross-validation via minimum criteria. The partial likelihood deviance (binomial deviance) curve was plotted versus log (lambda). Dotted vertical lines were drawn at the optimal values using the minimum criteria and the 1 SE of the minimum criteria (the 1-SE criteria). b LASSO coefficient profiles of the 2041 features. A coefficient profile plot was produced against the log (lambda) sequence. A vertical line was drawn at the value selected, using 10-fold cross-validation, where optimal lambda resulted in 15 features with nonzero coefficients. c ROC curves of radiomics signatures in primary cohorts. d Validation cohort
Clinical characteristics
There were no significant differences in the rate of LN metastasis (44.07 and 41.46% in the primary and validation cohorts, respectively, \( p = 0.772 \)) and clinical characteristics between the two cohorts, which confirmed their use as primary and validation cohorts. The differences in clinical characteristics between the LN metastasis-positive group and LN metastasis-negative group were not significant, except for CT-reported LN status and pathological grades in the primary and validation cohorts (Table 1).

Feature selection and radiomic signature construction
The results of the 2041 radiomics features for both LN metastasis-positive and -negative cases in the primary cohort are shown (Fig. 2). The heat map represents a color-coded array of all feature values (x-axis) in all cases (y-axis). Because there were redundant feature groups that may have affected the classification, we used the LASSO method and selected 15 optimal features with nonzero coefficients in the primary cohort, for constructing the radiomics signature prediction model (Fig. 3). The coefficients of each feature of the model are shown (Table 2). In the ROC analysis, the radiomics signature prediction model yielded an AUC of 0.922 [95% confidence interval (CI), 0.878–0.967] in the primary cohort and 0.890 (95% CI, 0.769–1) in the validation cohort (Fig. 3).

Establishment, validation and evaluation of clinical and combined prediction models
The radiomics signature, CT-reported LN status, and pathological grades were subjected to multivariable logistic regression analysis in the primary cohort (Table 3). Then, in the two cohorts, the clinical prediction model was built based on the two clinical characteristics, and the combined prediction model was built, based on the two clinical characteristics and radiomics signature. The clinical prediction model yielded an AUC of 0.666 (95% CI, 0.569–0.762) in the primary cohort and 0.713 (95% CI, 0.548–0.878) in the validation cohort. The combined prediction model yielded an AUC of 0.944 (95% CI, 0.905–0.982) in the primary cohort and 0.912 (95% CI, 0.778–1) in the validation cohort (Fig. 4). The IDI value of 0.5046 (95% CI, 0.4106–0.5986, \( p < 0.0001 \)) in the primary cohort and 0.3294 (95% CI, 0.1714–0.4875, \( p < 0.0001 \)) in the validation cohort indicated a significantly improved predictive ability of the combined prediction model, when compared with the clinical prediction model.

A nomogram was built based on the combined prediction model in the primary cohort (Fig. 5). The decision curve analysis for the nomogram showed that if the threshold probability of a patient and a doctor is 1 and 89%, respectively, then by using the radiomics nomogram to predict LN metastases, this adds more benefit than either the treat-all-patients scheme or the treat-none scheme. Within this range, the net benefit was comparable with several overlaps on the basis of the nomogram. The calibration curve of the combined prediction model in the two cohorts demonstrated good agreement between prediction and observation. The Hosmer-Lemeshow test yielded a non-significant statistic (\( p = 0.215 \) and 0.462, respectively) (Fig. 4).

Discussion
This study determined the correlation between certain radiomic signatures and preoperative LN metastasis, in a retrospective analysis of 159 patients with PDAC. A

---

**Table 2** List of selected feature parameters for establishing the radiomics signature

| Feature name and intercept | Coefficient |
|---------------------------|-------------|
| Intercept                 | −0.353      |
| original_firstorder_Skewness | −0.833     |
| log-sigma-1-0-mm3D_glszm_LowGrayLevelZoneEmphasis | 0.404 |
| log-sigma-1-0-mm3D_ngtdm_Busyness | 0.379 |
| wavelet-LLL_glcM_JointAverage | −14.890 |
| wavelet-LHL_glszm_SmallAreaLowGrayLevelEmphasis | −0.127 |
| wavelet-LHH_firstorder_Skewness | 1.068 |
| wavelet-LHH_glcM_Imc1 | 9.466 |
| wavelet-LHH_glcM_Imc2 | 2.352 |
| wavelet-LHH_glszm_SmallAreaEmphasis | −0.462 |
| wavelet-HLL_firstorder_Maximum | −4.677 |
| exponential_firstorder_Energy | −0.937 |
| exponential_glszm_SizeZoneNonUniformity | 3.390 |
| gradient_glcM_Jdn | 2.041 |
| gradient_glszm_SmallAreaLowGrayLevelEmphasis | 0.091 |
| lbp-3D-k_glszm_SmallAreaLowGrayLevelEmphasis | 3.205 |

**Table 3** Multivariable logistic regression analyses

| Intercept and variable | Combined prediction model in the primary cohort |
|------------------------|-----------------------------------------------|
|                        | Coefficient | Odds ratio (95% CI) | \( p \) |
| Intercept              | −0.461      | −                     | 0.499   |
| Radiomic signature     | 3.533       | 34.233 (7.344–159.575) | < 0.001 |
| CT-reported LN status  | 1.130       | 3.095 (0.941–10.174)  | 0.063   |
| Pathological grade     | 0.473       | 1.605 (0.755–3.412)   | 0.219   |
combined prediction model, based on the preoperative CECT imaging radiomics signature, CT-reported LN status, and pathological grade, was built to identify patients with LN metastasis before surgery. AUC values of 0.944 in the primary cohort and 0.912 in the validation cohort were obtained. This suggested that this model can be of clinical value for the diagnosis of preoperative LN metastasis in patients with PDAC.

The TNM-based staging system of the American Joint Committee on Cancer is commonly used for PDAC.
staging, with LN status being an important component [31]. Preoperative lymph node metastasis is an independent prognostic factor for PDAC and has an important impact on the choice of treatment strategies [7, 8, 32–35]. A French prospective multicenter study that included 147 patients, indicated that preoperative LN involvement had a greater effect on prognosis than resection margin status [36]. Another study showed that the prognosis of patients with preoperative LN metastasis positive PDAC can be improved by neo-adjuvant therapy for fibrosis of LNs [35]. Therefore, accurate preoperative diagnosis of LN status in patients with PDAC has important clinical significance. CA 19–9 levels are independent predictive indicators for LN metastasis [37], however, in this study, CA 19–9 levels had no statistical significance (p > 0.05). This observation may be related to sample size, therefore large-scale clinical trials are needed to verify this result. Traditionally, the diagnosis of preoperative LN status in PDAC depends on imaging examinations. Studies have shown that the accuracy of CECT diagnosis for LN metastasis is 48%, and even with 18-fluorodeoxyglucose PET/CT, the accuracy is only approximately 68% [38]. In this study, the diagnostic accuracy of CT-reported LN status in the primary cohort was 60, and 68% in the validation cohort. The AUCs of the clinical prediction model based on CT-reported LN status, and pathological grade in the primary cohort and validation cohort were 0.666 and 0.713, respectively. Considering that pathological grade is obtained from postoperative specimens, its predictive ability will be further reduced after removal pathological grade.

Radiomics has been recognized as an important technology for the conversion of digital medical images to mineable high-dimensional data, and great achievements have been made in recent years [19, 20, 39]. The application of radiomics to PDAC has generated optimism, but it is also challenging because of nonspecific clinical presentation and subtle imaging findings. Previous studies on the application of radiomics to PDAC have focused on prognostic assessments and differential diagnosis [40–43]. The current study used radiomics features of the entire 3D volume to assess preoperative LN status in patients with PDAC. A recent important study in colorectal cancer, revealed associations between CT radiomics and LN metastases [44], thereby providing a reference for this study. We used CT imaging, which is easily accessible as a routine examination method. The 2041 candidate radiomics features extracted from venous phase images were reduced to 15 potential predictors, and the radiomics signature was generated by shrinking the regression coefficients, with the LASSO method. The combined prediction model, including the radiomics signature and clinical characteristics, demonstrated adequate discrimination when compared with the clinical prediction model in the primary cohort (IDI, 0.5046), which was improved in the validation cohort (IDI, 0.3294). This indicated that the radiomics signature was stable and robust for LN metastasis prediction.

The present study had some limitations. Firstly, owing to the nature of a pilot study design, the radiomics analysis was retrospectively applied to single-center data, which lacked external validation. Multicenter data analysis will
be incorporated in future studies. Secondly, the radiomics signature of this study was obtained from the venous phase of CECT images, and multimodal parameters were lacking. Finally, we did not stratify the analysis of LN metastasis, although each case had exact pathological results.

Conclusion
In summary, this pilot study showed that a noninvasive radiomics signature, extracted from CECT images, can be conveniently used to predict preoperative LN metastasis in patients with PDAC.

Abbreviations
AUC: Area under the curve; CA19–9: Cancer antigen-19–9; CEA: Carcinoembryonic antigen; CEST: Contrast-enhanced CT; CT: COMPUTED tomography; IDI: Integrated discrimination improvement; IoU: Intersection-over-union; LASSO: The least absolute shrinkage and selection operator; LN: Lymph node; PDAC: Pancreatic ductal adenocarcinoma; ROC: Receiver operating characteristic; ROI: Region of interest; TBIL: Total bilirubin

Acknowledgements
Not applicable.

Authors’ contributions
Study concept and design: WC and ZLZ; All the authors contributed to the data analysis and interpretation. KL and QDY performed the statistical analysis; KL, QDY, ML and JLY extracted the texture features. WJH, MSD, KC, YO, JL, XQW and HRL contributed to the MRI data acquisition. KL, QDY and JYX were major contributors and contributed equally to writing the first draft. JJX and ZLZ contributed to manuscript review. All authors have read and approved the final manuscript.

Funding
This research was supported by the National Key Research and Development plan of China (NO. 2016YFC1100501 and NO. 2016YFC0103100) and the National Natural Science Foundation of China (NO. 61701506), and the Science and Technology Innovation Program of Social Undertakings and People’s Livelihood Security of Chongqing Science and Technology Commission (cstc2016shms-xtzx10002).

Availability of data and materials
The datasets supporting the conclusion of this article available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Ethical approval was obtained from the Ethics Committee of Southwest Hospital, Third Military Medical University (approval No.KY201802) and informed consent requirements were waived.

Consent for publication
Written informed consent was obtained from each patient.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Radiology, Southwest Hospital, Army Medical University, Chongqing 400038, China. 2Department of Radiology, Sichuan Science City Hospital, Mianyang, Sichuan, China. 3Department of Medical Engineering, Xinqiao Hospital, Army Medical University, Chongqing, China. 4Hepatopancreato-biliary Surgery, Southwest Hospital, Army Medical University, Chongqing, China. 5Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Received: 30 October 2019 Accepted: 13 January 2020
Published online: 30 January 2020

References
1. Segel RL, Miller KD, DvK AJ. Cancer statistics, 2018. Ca A Cancer J Clin. 2018;68:11.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Mattison LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.
3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17.
4. Zhang Q, Zeng L, Chen Y, Lian G, Qian C, Chen S, Li J, Huang K. Pancreatic Cancer epidemiology, detection, and management. Gastroenterol Res Pract. 2016;2016:8962321.
5. Dimastromatteo J, Houghton JL, Lewis JS, Kelly KA. Challenges of pancreatic Cancer. Cancer J. 2015;21:188–93.
6. Conroy T, Bachet JB, Ayav A, Huquet F, Lambert A, Cararella M, Marechal R, Van Laethem JL, Ducruex M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10–22.
7. Basturk O, Saka B, Balci S, Postlevait LM, Knight J, Goodman M, Kooby D, Samiento JM, El-Rayes B, Choi H, et al. Substaging of lymph node status in resected pancreatic ductal adenocarcinoma has strong prognostic correlations: proposal for a revised N classification for TNM staging. Ann Surg Oncol. 2015;22(Suppl 3):S1187–95.
8. Paella S, Sandini M, Giancinti L, Butturini G, Salvia R, Bassi C. The prognostic impact of Para-aortic lymph node metastasis in pancreatic cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2016;42:616–24.
9. Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, Andreini-Sandberg A, Asibun HJ, Beckhorn M, Buchler MW, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the international study group on pancreatic surgery (ISGPS). Surgery. 2014;156:591–600.
10. Tran Cao HS, Zhang Q, Sada YH, Silberfein EJ, Hsu C, Van Buren G 2nd, Chai C, MMK F, Fisher WE, Massirweh NN. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Surgery. 2017;162:557–67.
11. Moriya T, Kimura W, Hirai T, Takasu N, Mizutani M. Expression of MUC1 and MUC2 in ampullary cancer. Int J Surg Pathol. 2011;19:941–7.
12. Wang SC, Parekh JR, Porembka MR, Nathan D, D’Angelica MJ, DeMatteo RP, Fong Y, Kenghing TP, Jamagin WR, Allen PJ. A pilot study evaluating serum MMP7 as a preoperative prognostic marker for pancreatic ductal adenocarcinoma patients. J Gastrointest Surg. 2016;20:899–904.
13. Tao L, Zhang L, Peng Y, Tao M, Li G, Xi D, Yuan C, Ma C, Jiang B. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC). Oncotarget. 2016;7:74314–24.
14. Roche CJ, Hughes ML, Garvey CJ, Campbell E, White DA, Jones L, Neoptolemos JP, CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol. 2003;180:475–80.
15. Briz MG, Natalie L, Manfredi R, Barbaro B, Vecchioni A, Mariano P. Staging of pancreatic ductal adenocarcinoma with spiral CT and MRI. Rads. 2001;26:155–9.
16. Tseng DS, van Santvoort HC, Feghachi S, Besselec MG, Zuidhof NP, Borel Rinkes IH, van Leeuwen MS, Molenar IQ. Diagnostic accuracy of CT in assessing extra-regional lymphadenopathy in pancreatic and peri-ampullary cancer: a systematic review and meta-analysis. Surg Oncol. 2014;23:229–35.
17. Fong ZY, Tan WP, Lavu H, Kennedy EP, Mitchell DG, Koniaris LG, Sauter PK, Rosato EL, Yeo CJ, Winter JM. Preoperative imaging for resectable periampullary cancer: clinicopathologic implications of reported radiographic findings. J Gastrointest Surg. 2013;17:1098–106.
18. Aerts HJ, Velazquez ER, Leejenaar RT, Pannar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.
19. Gilleens RI, Kinneran PE, Hricak H. Radiomics: images are more than pictures, They Are Data. Radiology. 2016;278:563–77.
20. Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z, Liang C, Tian J, Liang C. Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (I or II) non-small cell lung cancer. Radiology. 2016;281:947–57.
21. Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol. 2016;61:R150–66.
22. Permutth JB, Choi J, Balaranatham Y, Kim J, Chen DT, Chen L, Orcutt S, Doepker MP, Gage K, Zhang G, et al. Combining radiomic features with a miRNA classifier may improve prediction of malignant phenotype for pancreatic intraductal papillary mucinous neoplasms. Oncotarget. 2016;7:85785–97.
23. Hanania AN, Bantis LE, Feng Z, Wang H, Tamir EP, Katz MH, Maitra A, Koay EJ. Quantitative imaging to evaluate malignant potential of IPMNs. Oncotarget. 2016;7:85776–84.
24. Li ZS, Li Q. The latest 2010 WHO classification of tumors of digestive system. Zhonghua Bing Li Xue Za Zhi. 2011;40:351–4.
25. Chun YS, Pawlik TM, Vauthey JN. 8th edition of the AJCC Cancer staging manual: pancreas and Hepatobiliary cancers. Ann Surg Oncol. 2018;25:5845–7.
26. Fargnoli R, Fusi I. Computerized tomography of pancreatic tumors. Tumori. 1999;85:53–5.
27. de Savornin Lohman EAJ, de Bitter TJJ, van Laarhoven C, Hermans JJ, de Haas RJ, de Reuver PR. The diagnostic accuracy of CT and MRI for the detection of lymph node metastases in gallbladder cancer: a systematic review and meta-analysis. Eur J Radiol. 2019;110:56–62.
28. Stayerb B, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26:5512–28.
29. Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: the Hosmer-Lemeshow test revisited. Crit Care Med. 2007;35:2052–6.
30. Vickers AJ, Cronin AM, Elkin EB, Siewert J. Extentions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. Bmc Med Inform Decis Mak. 2008;8:53.
31. Shin D W, Lee J, Kim J, et al. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2019;45(11):2159–65.
32. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Tsunoda T, Sueda T. Prognostic impact of Para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma. World J Surg. 2010;34:1900–7.
33. Kim SH, Hwang HK, Lee WJ, Kang CM. Identification of an N staging system that predicts oncologic outcome in resected left-sided pancreatic cancer. Medicine (Baltimore). 2016;95:e4035.
34. Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, MacDonald JS, Willett CG. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemotherapy for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys. 2011;81:1328–35.
35. Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, et al. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:1168–75.
36. Delpero JR, Jeune F, Bacheller P, Regenet N, Le Treut YP, Paye F, Caresse N, Sauvanet A, Adham M, Autret A, et al. Prognostic value of resection margin involvement after Pancreatoduodenectomy for ductal adenocarcinoma: updates from a French prospective multicenter study. Ann Surg. 2017;266:787–96.
37. Zhou G, Liu J, Chen H, et al. Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-alpha and TSGF after cryosurgery in pancreatic cancer patients. Biotechnol Lett. 2012;34:1235–41.
38. Cui D, Peng Y, Zhang C, et al. Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy. J Clin Invest. 2018;128(11):4997–5007.
39. Kickingereder P, Goetz M, Muschelli J, Wick A, Neuberger U, Shinohara RT, Sill M, Nowosielski M, Schlemmer HP, Radbruch A, et al. Large-scale Radiomic profiling of recurrent Glioblastoma identifies an imaging predictor for stratifying anti-Angiogenic treatment response. Clin Cancer Res. 2016;22:5765–71.
40. Elaghi A, Baig S, Zhang Y, Zhang J, Karianicolas P, Gallinger S, Khalvati F, Haider MA. CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma - a quantitative analysis. BMC Med Imaging. 2017;17:38.
41. Casinotto C, Chong J, Zogopoulos G, Reinhold C, Chiche L, Lafuente JC, Cugna A, Terrebonne E, Dohan A, Gallix B. Resectable pancreatic adenocarcinoma: role of CT quantitative imaging biomarkers for predicting pathology and patient outcomes. Eur J Radiol. 2017;90:152–8.